A neurotoxic amino acid called β-N-methylamino-L-alanine (BMAA) fed to vervet monkeys caused damage to the spinal cord similar to what is seen in amyotrophic lateral sclerosis (ALS), potentially making them a much-needed new animal model for research, a study reported. Adding L-serine, a non-toxic amino acid, to their diet…
News
Starting a 501(c)(3) tax-exempt nonprofit isn’t easy, but the National Organization for Rare Disorders gave a few tips for those looking to begin the complex process in its Feb. 20 webinar. William Whitman…
Aiforia Technologies and NeuroScience Associates (NSA Labs) are collaborating in an effort to learn more about how amyotrophic lateral sclerosis (ALS) affects brain function. The project leverages NSA Lab’s neuroscience expertise and Aiforia’s artificial intelligence (AI) know-how. It came about after the donation of the entire…
News
Enclear Receives Key Funding to Advance Therapies that Clear Toxic Proteins from Brain, Spinal Cord
Biotech company EnClear Therapies has announced $10 million in financing to help advance its proprietary platform for stopping the progression of neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). The investments comes from a Series A financing round, which is part of an early development stage for start-up…
Mutations in the C9ORF72 gene, the most common cause of amyotrophic lateral sclerosis (ALS), lead to changes in how cells process ribonucleic acid (RNA) and protein, a new study shows, shedding light on the mechanisms through which such mutations…
Neuropore Therapies was awarded a $500,000 grant from The ALS Association to advance in preclinical work its neural protective candidate, NPT1220-312, as a potential treatment of amyotrophic lateral sclerosis (ALS). The company is aiming to bring its molecule into clinical testing late next year. NPT1220-312 is a…
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
The protein synaptotagmin 13 (SYT13) protected motor neurons from degeneration in cell and animal models of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), a study reports, suggesting a gene therapy based on this protein’s related gene, SYT13, would treat these and other diseases of motor nerve cells.
Impaired processing and buildup of protein aggregates associated with amyotrophic lateral sclerosis (ALS) are linked to a protein that regulates the uptake of substances into the cell, a process known as endocytosis, a study found. Enhancing endocytosis may be an…
People with amyotrophic lateral sclerosis (ALS) may benefit from at-home monitoring using an app, a study found. The study, “Telehealth as part of specialized ALS care: feasibility and user experiences with ‘ALS home-monitoring and coaching’,” was published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Providing…
Recent Posts
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy